Key statistics
On Monday, Abeona Therapeutics Inc (0H7R:LSE) closed at 5.09, 32.55% above the 52 week low of 3.84 set on Nov 12, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 5.09 |
| Low | 5.09 |
| Bid | -- |
| Offer | -- |
| Previous close | 5.10 |
| Average volume | 7.52k |
|---|---|
| Shares outstanding | 54.19m |
| Free float | 46.73m |
| P/E (TTM) | 4.63 |
| Market cap | 277.46m USD |
| EPS (TTM) | 1.11 USD |
Data delayed at least 20 minutes, as of Mar 02 2026 16:57 GMT.
More ▼
Announcements
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
- Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
- Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates
- Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
More ▼
